

15 January 2013 EMA/HMPC/346737/2011 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on Juglans regia L., folium

Draft

Discussion in Working Party on Community monographs and Community	May 2011	
list (MLWP)	March 2012	
	May 2012	
	September 2012	
	November 2012	
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	15 January 2013	
for consultation	15 January 2015	
End of consultation (deadline for comments). Comments should be	15 April 2012	
provided using this template to hmpc.secretariat@ema.europa.eu	15 April 2013	
Rediscussion in Working Party on Community monographs and		
Community list (MLWP)		
Adoption by Committee on Herbal Medicinal Products (HMPC)		

KeywordsHerbal medicinal products; HMPC; Community herbal monographs; traditional
use; Juglans regia L., folium; Juglandis folium; Walnut Leaf

BG (bălgarski): Орех, лист	LT (lietuvių kalba): Graikinių riešutmedžių lapai
CS (čeština): Ořešákový list	LV (latviešu valoda): Valrieksta lapas
DA (dansk): Valnødblad	MT (malti): Ġewż
DE (Deutsch): Walnussblätter	NL (nederlands): Walnoot, Okkernoot
EL (elliniká): Καρύας φύλλο	PL (polski): Liść orzecha włoskiego
EN (English): Walnut Leaf	PT (português): Nogueira, folha
ES (espanol): Nogal, hoja de	RO (română): Frunză de nuc
ET (eesti keel): Pähklipuuleht	SK (slovenčina): Orechový list
FI (suomi): Saksanpähkinä, lehti	SL (slovenščina): List navadnega oreha
FR (français): Noyer (feuille de)	SV (svenska): Valnötsblad
HU (magyar): Diólevél	IS (íslenska):
IT (italiano): Noce foglia	NO (norsk): Valnøttblad

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on Juglans regia L., folium

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition¹

Well-established use	Traditional use
	 With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended Juglans regia L., folium, (walnut leaf) i) Herbal substance Not applicable ii) Herbal preparations Comminuted herbal substance

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance for decoction preparation for cutaneous use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product for the relief of minor inflammatory conditions of the skin. Indication 2)
	Traditional herbal medicinal product used in excessive perspiration of hands and feet.
	The product is a traditional herbal medicinal product for use in the specified indications exclusively based upon long-standing use.

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

Well-established use	Traditional use
	Posology
	Adults and elderly Indication 1)
	4-6 g of the comminuted herbal substance in 200 ml of boiling water as a decoction.
	Apply as a impregnated dressing to the affected areas of the skin 2 - 4 times daily.
	Indication 2)
	4-6 g of the comminuted herbal substance in 200 ml of boiling water as a decoction.
	Apply as a impregnated dressing to the affected areas of the skin up to 30 minutes twice daily.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Not to be used for more than 1 week.
	If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Cutaneous use.

4.2. Posology and method of administration²

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.
	Open wounds and large skin injuries.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use will discolour the skin.
	The use in children and adolescents under 18
	years of age has not been established due to lack

² For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
	of adequate data.
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	None known.
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

15 January 2013